To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved.

Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation ...

Ex-co-head of life sciences at previous firm brings expertise in multi-jurisdictional patent disputes involving supplementary protection certificates and second medical use claims. If you don't have a ...

Government unveils £8M OpenBind consortium to lead in AI drug discovery | Project to build world’s largest drug–protein ...

Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to ...

Three seasoned lawyers with experience in biotech, pharmaceutical, and medical device patent matters join the firm's practice ...

Unified Patent Court announces new case management system this summer | Release will be in two phases, with first phase ...

Two years since the UPC opened its doors, various developments might influence the UK government to reassess its position, ...

US appeals court confirms validity of Acadia's Nuplazid patents | Decision fends off generics from MSN Laboratories and ...

Two decisions by acting USPTO director Coke Morgan Stewart have “damaging” consequences, warns Vidal | Stewart kickstarts campaign of implied criticism of predecessor’s record. Already registered?

Office’s acting director lifts severe penalties against patent owner following Federal Circuit remand | Issues separate decision highlighting consequences of “lengthy awareness” of patent portfolio.

The firm’s new practice unites Faber’s transactional and licensing abilities with Crowell’s regulatory and litigation services, bringing together 50 professionals and expanding into Boston.